Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

Launched by MASSACHUSETTS GENERAL HOSPITAL · Oct 11, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how common a condition called transthyretin amyloidosis (ATTR) is in patients who have a specific type of heart failure known as Heart Failure with Preserved Ejection Fraction (HFpEF). This means that although their heart pumps normally, they still have heart failure symptoms. The researchers want to find out how often ATTR occurs in these patients and how to predict which heart failure patients might have this condition. The goal is to identify ATTR early so that patients can start receiving the right treatment sooner.

To participate in this trial, you need to be at least 65 years old and have a confirmed diagnosis of HFpEF. However, if you have severe kidney disease, a known diagnosis of amyloidosis, or some other specific heart conditions, you may not be eligible. If you join the study, you can expect to undergo some tests, including a scan that takes about 15 minutes. The study is currently recruiting participants, and it aims to improve the understanding and treatment of heart failure related to ATTR.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with a confirmed diagnosis of HFpEF.
• • Age ≥65 years old
• Exclusion Criteria:
• • End stage chronic kidney disease on dialysis (CKD stage 5 as defined as eGFR \<15mL/min)
• • no history of HFrEF (LVEF\<40%) with the exception of low LVEF in the setting of acute decompensation, AF RVR, ACS/MI, etc
• • Negative 99mTc-pyrophosphate scan within a year
• • Unable to lie down for 15 minutes for the 99mTc-pyrophosphate scan
• • Known diagnosis of amyloidosis
• • Severe valvular heart disease that is uncorrected (moderate to severe is considered exclusionary)